Sugawara Tamie, Ohkusa Yasushi, Taniguchi Kiyosu, Miyazaki Chiaki, Momoi Mariko Y, Okabe Nobuhiko
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
National Hospital Organization Mie National Hospital, Mie, Japan.
Drug Discov Ther. 2020 Mar 8;14(1):50-53. doi: 10.5582/ddt.2019.01091. Epub 2020 Feb 26.
Our earlier study investigated the incidence of severe abnormal behavior associated with neuraminidase inhibitors (NIs), but some studies have specifically examined the association of oseltamivir use and moderately abnormal behavior. Therefore, this study was undertaken to assess associations between moderately abnormal behavior and administered drugs. All cases of patients with influenza who exhibited moderately abnormal behavior were reported to us by physicians of all sentinel clinics and hospitals for influenza throughout Japan. Open Data of the National Database of Electronic Medical Claims include the numbers of patients diagnosed as having influenza who were prescribed NI. Incidence by NI was tested using Fisher's exact test. We received 518 moderately abnormal cases in 5-9-year-olds and 207 moderately abnormal behavior cases in 10-19-year-olds. The incidence among NI ranged from 193 per one million influenza patients in laninamivir among 10-19-year-olds to 1021 for peramivir among 5-9-year-olds. Estimation results revealed the order of risk among NIs as peramivir, oseltamivir, zanamivir and laninamivir in moderate abnormal behavior. Because of data limitations, risk among patients with and without NI cannot be compared.
我们早期的研究调查了与神经氨酸酶抑制剂(NIs)相关的严重异常行为的发生率,但一些研究专门研究了使用奥司他韦与中度异常行为之间的关联。因此,本研究旨在评估中度异常行为与所用药物之间的关联。日本各地所有流感定点诊所和医院的医生向我们报告了所有表现出中度异常行为的流感患者病例。国家电子医疗索赔数据库的开放数据包括被诊断患有流感并开具了神经氨酸酶抑制剂处方的患者数量。使用Fisher精确检验对神经氨酸酶抑制剂的发病率进行了测试。我们收到了518例5至9岁儿童的中度异常病例和207例10至19岁儿童的中度异常行为病例。神经氨酸酶抑制剂的发病率范围从10至19岁儿童中拉尼米韦每百万流感患者193例到5至9岁儿童中帕拉米韦每百万流感患者1021例。估计结果显示,在中度异常行为方面,神经氨酸酶抑制剂的风险顺序为帕拉米韦、奥司他韦、扎那米韦和拉尼米韦。由于数据限制,无法比较使用和未使用神经氨酸酶抑制剂患者的风险。